To study the clinical effect of magnesium isoglycyrrhizinate combined with ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Methods:A total of 118 PBC patients in January 2014——December 2012 treated in our hospital patients were randomly divided into combined group and control group with 59 cases in each group. There were no significant differences of two groups′ general data of patients (P>0.05). On the basis of conventional therapy, the control group treated with ursodeoxycholic acid treatment, combined group were given magnesium isoglycyrrhizinate based on the treatment of control group. The clinical symptoms and signs, liver biochemical indexes, IgA, IgG, IgM, adverse reactions and clinical curative effect index of two groups were observed before and after treatment. Results:Symptoms like fatigue, dry mouth, anorexia, skin itching, TBiL, ALP, ALT, AST, GGT, TG, TCH gamma, IgA, IgG, IgM and other indicators were improved in the two groups after treatment, P<0.05, while the combined group had significantly better results than the control group, P<0.05. The total effective rate of combined group was 84.75%, significantly higher than that of the control group (64.41%), P<0.05. The incidence rate of adverse reaction of treatment of the combined group was 6.87% and the control group was (5.08%), the difference was not significant, P<0.05.Conclusion:Ursodeoxycholic acid combined with magnesium isoglycyrrhizinate can effectively improve PBC patients′ clinical symptoms and signs, improve the biochemical indexes of immune regulation with low adverse the reaction, which is worthy of application in clinic.